CN1552433A - Chinese medicine preparation for treating respiratory tract infection and virus flu, preparing method thereof - Google Patents
Chinese medicine preparation for treating respiratory tract infection and virus flu, preparing method thereof Download PDFInfo
- Publication number
- CN1552433A CN1552433A CNA200310122718XA CN200310122718A CN1552433A CN 1552433 A CN1552433 A CN 1552433A CN A200310122718X A CNA200310122718X A CN A200310122718XA CN 200310122718 A CN200310122718 A CN 200310122718A CN 1552433 A CN1552433 A CN 1552433A
- Authority
- CN
- China
- Prior art keywords
- preparation
- volatile oil
- herba schizonepetae
- chinese medicine
- medicine preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 206010057190 Respiratory tract infections Diseases 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 62
- 238000000034 method Methods 0.000 title claims description 18
- 241000700605 Viruses Species 0.000 title description 8
- 230000003612 virological effect Effects 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 5
- 239000000341 volatile oil Substances 0.000 claims description 39
- 239000008187 granular material Substances 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 21
- 241000628997 Flos Species 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000000605 extraction Methods 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 15
- 206010022000 influenza Diseases 0.000 claims description 14
- 229920000858 Cyclodextrin Polymers 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 11
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims description 10
- 241001299553 Ilex chinensis Species 0.000 claims description 10
- 241001100935 Ilex purpurea Species 0.000 claims description 10
- 235000003366 Ilex purpurea Nutrition 0.000 claims description 10
- 238000007796 conventional method Methods 0.000 claims description 10
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- -1 filters Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 7
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000001256 steam distillation Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- 238000005498 polishing Methods 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 241000951473 Schizonepeta Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 description 19
- 230000000694 effects Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000009254 shuang-huang-lian Substances 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 241000712461 unidentified influenza virus Species 0.000 description 7
- 241000194017 Streptococcus Species 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 241000588747 Klebsiella pneumoniae Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000002155 anti-virotic effect Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 229960003371 protocatechualdehyde Drugs 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 3
- 238000011951 anti-virus test Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 229940100050 virazole Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000193468 Clostridium perfringens Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241001113283 Respirovirus Species 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229950005162 benexate Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940106164 cephalexin Drugs 0.000 description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 2
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical group C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 238000009603 uroscopy Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine for treating respiratory tract infection and viral cold is prepared from 9 Chinese-medicinal materials including schizonepeta, honeysuckle flower, dandelion herb, liquorice root, etc.
Description
Technical field
The present invention relates to the field of Chinese medicines.Be specifically related to a kind of Chinese medicine preparation and preparation method for the treatment of respiratory tract infection and viral influenza.
Background technology
Flu is worldwide commonly encountered diseases, frequently-occurring disease, and bigger to human beings'health harm, its complication is more, as myocarditis, pneumonia etc., but the severe patient threat to life.Especially virogenetic flu, chemical synthetic drug is not remarkable to its curative effect, and more side reaction is arranged, and actively obtains effective antibacterial and detoxicating medicament from plant, and Chinese medicine has greater advantage and potentiality in this respect.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of quality of the pharmaceutical preparations stable according to Chinese medical theory, and determined curative effect, safety are convenient to deposit and the treatment respiratory tract infection used and the Chinese medicine Jing Yin preparation of viral influenza.
The Chinese medicine preparation of treatment respiratory tract infection disclosed by the invention and viral influenza is to be the oral formulations that active component is made with Herba Schizonepetae, Flos Lonicerae, Ilex purpurea Hassk.[I.chinensis Sims, Herba Houttuyniae, Folium Isatidis, Herba Taraxaci, Radix Saposhnikoviae, Fructus Arctii and Radix Glycyrrhizae, and wherein the percentage by weight of each raw material of active component is formed preferred Herba Schizonepetae 3-11%, Flos Lonicerae 3-11%, Ilex purpurea Hassk.[I.chinensis Sims 11-21%, Herba Houttuyniae 11-21%, Folium Isatidis 11-21%, Herba Taraxaci 11-21%, Radix Saposhnikoviae 3-11%, Fructus Arctii 3-11% and Radix Glycyrrhizae 2-8%.
Each active raw materials of the present invention is extracted the acquisition extract through suitable solvent, makes various medically acceptable various peroral dosage forms with pharmaceutic adjuvant, comprises granule, capsule, oral liquid or tablet etc., measures the content of protocatechualdehyde in the preparation with HPLC.
Another technical problem to be solved by this invention is to disclose the preparation method of the Chinese medicine preparation of above-mentioned treatment respiratory tract infection and viral influenza.
The preparation of Chinese medicine preparation of the present invention specifically comprises:
Directly each active raw materials water or alcohol are decocted extraction acquisition concentrated extract, make various preparations according to a conventional method.
Preferable method is to extract earlier the volatile oil of Herba Schizonepetae or Flos Lonicerae, will extract then that other medical materials of respectively distinguishing the flavor of merge in residue and the prescription behind the volatile oil, concentrates acquisition extractum after water or the alcohol extraction; The volatile oil that from Herba Schizonepetae, extracts can be directly or with behind the cyclodextrin inclusion technique enclose with extract extractum and pharmaceutic adjuvant and make various preparations according to a conventional method.
Preferred each formulation preparation method of the present invention comprises:
(1) preparation of mixture
Get the medicinal component of recipe quantity and add extraction solvent decoction secondary, collecting decoction filters, and filtrate concentrating made.
(2) preparation of oral liquid
Get the Herba Schizonepetae and the Flos Lonicerae of recipe quantity and extract volatile oil, the aqueous solution after distillation device is in addition collected.
Herba Schizonepetae behind the extraction volatile oil and Flos Lonicerae medicinal residues and the medicinal component of remaining recipe quantity add extraction solvent and decoct secondary, collecting decoction, filter, filtrate concentrates, and adds precipitant, place, get supernatant and filter, concentrate aqueous precipitation, filter, concentrate, aqueous solution, correctives and antiseptic after adding volatile oil and distilling are made oral liquid according to a conventional method.
(3) solid preparation preparation
A. extract volatile oil: the Herba Schizonepetae of getting recipe quantity is extracted volatile oil, and other puts; Or with volatile oil cyclodextrin inclusion technique enclose, place, filter, washing, drying makes the cyclodextrin clathrate that contains Herba Schizonepetae volatile oil;
B. get the medicinal component of recipe quantity except that Herba Schizonepetae, add the residue after Herba Schizonepetae is extracted volatile oil, add extraction solvent and decoct secondary, collecting decoction filters, and filtrate concentrates, and adds precipitant, and placement is spent the night, and gets supernatant and makes clear paste;
C. get step B and make clear paste and pharmaceutic adjuvant, contain Herba Schizonepetae volatile oil cyclodextrin clathrate mix homogeneously, make granule, capsule or tablet according to a conventional method;
Or get that step B makes clear paste and the pharmaceutic adjuvant mix homogeneously is made granule, or the drying technology makes fine powder, sprays into Herba Schizonepetae volatile oil, makes solid preparation according to a conventional method.
Extraction solvent of the present invention is selected from the alcoholic solution of water or 30-90%.
Precipitant of the present invention is the 75-95% alcoholic solution.
Pharmaceutic adjuvant of the present invention is a pharmaceutic adjuvant commonly used in the preparation.
Herba Schizonepetae volatile oil cyclodextrin inclusion technique of the present invention can be saturated water solution method (electronic paddling process, ultrasonic method, high speed tissue are smashed method to pieces), polishing, liquid-liquid method, wherein used enclose material is a cyclodextrin, comprises beta-schardinger dextrin-or hydroxypropyl.
Essential oil extraction method of the present invention comprises steam distillation or super critical extraction.
Dry technology of the present invention comprises vacuum drying, spray drying and Freeze Drying Technique.
A technical problem more to be solved by this invention is to disclose the application of above-mentioned preparation in preparation treatment respiratory tract infection and viral influenza medicine.
It is the respiratory tract infection and the viral influenza of primary symptom with heating, aversion to wind, pharyngalgia, cough that Chinese medicine preparation of the present invention is specially adapted to treat the wind and heat in the lung meridian card.
Oral each dosage is the preparation that contains protocatechualdehyde 0.6-2.6mg, and obey 2-3 every day.
The active component prescription is got the meaning of Lonicerae and Forsythiae Powder in the preparation of the present invention, relieving the exterior syndrome with drugs of pungent in flavor and cool in nature, and heat-clearing and toxic substances removing, and overweight heat clearing away.
Epidemic febrile disease from the beginning of, evil defending branch, harmony is in throat on the wind heat, Lung Qi obstraction is felt in pathogenic warmth, so the disease of heating, pharyngalgia, cough is arranged, the wind person dredges it, disease with heat symptoms should be treated by cooling, controlling should the dispelling wind expelling pathogenic factors from the exterior, heat-clearing and toxic substances removing.
Herba Schizonepetae, Flos Lonicerae are monarch drug in the side, and the hot temperature of Herba Schizonepetae is discongested, and is warm and not dry, goes into lung liver two warps, for controlling the principal agent of pathogenic wind-warm.Compendium of Material Medica records: " loose wind heat, refresh oneself, throat, clear scar of Herba Schizonepetae swells, controls stiffness of the nape." Zhang Shanlei also says: " and Herba Schizonepetae little suffering of distinguishing the flavor of, and band fragrance, its gas is very clear, and matter lightly floats again, and the heat of leaking informaton, can be let out lung-heat and reaches fur last all diseases at table, and the cough due to pathogenic wind-heat be shoulded it, and wind heat headache due to invasion of exogenous pathogens cold and heat also are principal agents." Flos Lonicerae sweet in the mouth cold in nature, go into lung, stomach, the heart, spleen channel, heat-clearing and toxic substances removing has a surname's expelling pathogenic factors from the exterior that looses again, and not only clearing heat in QI system, but also the branch heat that can purify the blood also can be induced sweat.The Compendium of Material Medica record: " it is swollen that Flos Lonicerae cures mainly the cold and heat body, all toxic swellings, heat radiation detoxifcation." be the key medicine of heat-clearing and toxic substances removing, its main component is chlorogenic acid chemical compound, flavonoid and xylostein etc.Modern pharmacological research proof Flos Lonicerae antibacterial range is bigger, and Gram-positive, negative bacterium are all had inhibitory action, and Respirovirus such as influenza Asia first type, dust arc virus (ECHO 11) and herpesvirus are all had certain inhibitory action.Prescription is equipped with the merit that Radix Saposhnikoviae helps the Herba Schizonepetae dispelling wind to relieve the exterior syndrome, but power relaxes, and makes slight perspiration and heat is moved back it, and Li Gao is referred to as meaning: " the profit agent also in the wind." more being equipped with Folium Isatidis, Ilex purpurea Hassk.[I.chinensis Sims, Herba Taraxaci, dosage is heavier, focuses in heat-clearing and toxic substances removing, and the heat of lung heat clearing is to be ministerial drug, and assistant is with Herba Houttuyniae, Fructus Arctii dispersing lung-QI and dissipating phlegm, resolving toxin and disinhibiting the throat.Radix Glycyrrhizae detoxifcation and in, coordinating the actions of various ingredients in a prescription is messenger drug for it.
Above-mentioned each medicine side of being combined into has the dispelling wind expelling pathogenic factors from the exterior, heat-clearing and toxic substances removing, and the merit of lung qi dispersing sore-throat relieving is used for the treatment of anemopyretic cold and violates heating, pharyngalgia, cough due to exterior syndrome and the wind-warm lung-heat disease syndrome of wind-heat invading lung.The hot cold of prescription is then flat, and bitter cold is then fallen, and tool is made a distinction between the important and the lesser one, treating both the principal and secondary aspects of a disease, eliminating evil and do not hinder positive characteristics.
With the pharmacodynamics test that Chinese medicine preparation of the present invention (Jing Yin granule) has carried out relevant antivirus test and preventing respiratory infection, the result is as follows:
1. antivirus test
1.1. extracorporeal antivirus effect test
1.1.1. toxicity test to the Hep-2 cultured cell
Observe by toxicity test, two kinds of dilution Jing Yin granule medicinal liquid cell growth of 0.85mg/ml, 1.70mg/ml do not have obvious influence, make antivirus test usefulness so get these two kinds of dilution medicinal liquids.
1.1.2. influence to the pathological changes caused by virus effect
Be subjected to examination virus: parainfluenza-1, RSV, CoxB
4, CoxB
5, CoxB
6, ADV
3, ADV
7, HSV-I, HSV-II.
Table 1 Jing Yin granule is to the influence of pathological changes caused by virus effect
Virus-virus azoles Jing Yin granule
0.125mg/ml 0.85mg/ml 1.70mg/ml
Parainfluenza-1 ++++
RSV ++ ++ ++
CoxB
4 + - +
CoxB
5 + + +
CoxB
6 + + +
ADV
3 + + +
ADV
7 + + +
HSV-I + + ++
HSV-II + + +
The result as seen, the Jing Yin granule all has stronger inhibitory action to 9 kinds of viruses of try, in institute's amount of reagent (0.85mg/ml, 1.70mg/ml) scope, inhibition strength is suitable with the positive control drug virazole, not only 5 kinds of RNA viruses institute cytopathogenic effects such as RSV there is in various degree inhibitory action, and to ADV
3Etc. the caused cytopathic effect of DNA viruses the obvious suppression effect is also arranged, show that the particulate antivirus action of Jing Yin is wider.
1.2. the interior effect of body to influenza virus
1.2.1. effect to mice influenza virus property pneumonia
The influence that table 2 Jing Yin granule becomes pneumonopathy due to the mouse infection influenza virus
Group dosage Mus is counted lung exponential quantity suppression ratio
The P value
(g/kg/d) (only) (M ± S) (I%)
Virus control--11 1.58 ± 0.23
Normal control--11 1.00 ± 0.12
Virazole 0.07 11 1.08 ± 0.14 31.34＜0.01
Jing Yin granule 5.0 10 1.23 ± 0.13 22.14＜0.01
10.0 9 1.30±0.18 17.83 ＜0.01
With 5,10g/kg/d irritates the stomach mice, can significantly alleviate the lung index of infecting mouse, because influenza infection causes pneumonia, along with the infiltration of inflammation, ooze out, lung weight increased, the lung exponential quantity raises.The size of lung weight has reflected the order of severity of pneumonia, and the Jing Yin granule can significantly reduce the lung index of infecting mouse, shows the degree that can alleviate pneumonia due to the influenza virus.
1.2.2. influence to proliferation of influenza virus amount in the mouse lung
Table 3 Jing Yin granule is to the influence of proliferation of influenza virus amount in the mouse lung
Dosage Mus number is checked positive positive rate suppression ratio
Group P value
(g/kg/d) (M ± S) (%) (I%) for (only) total number
Virus control 0.00 9 329 226 68.97 ± 3.90
Virazole 0.07 9 302 139 46.02 ± 6.80 33.27＜0.01
Jing Yin granule 5.0 9 213 118 55.53 ± 4.64 19.49＜0.01
10.0 9 191 104 54.45±2.95 20.37 ＜0.01
Table 3 is the result show, the Jing Yin granule in institute's amount of reagent scope to mouse lung in the proliferation of influenza virus amount significant inhibitory effect is all arranged.
Above internal and external test shows that the Jing Yin granule has good antivirus action, and dying for clinical treatment respirovirus sexuality provides pharmacological basis.
2. in-vitro antibacterial test
2.1. tube dilution method
With the positive contrast medicine of SHUANGHUANGLIAN KELI, testing drug is to staphylococcus aureus, colon bacillus, staphylococcus epidermidis, A group streptococcus, the antibacterial action of Klebsiella Pneumoniae, clostridium perfringen.
Jing Yin granule and SHUANGHUANGLIAN KELI 50mg/ml do not have antibiotic effect to colon bacillus, clostridium perfringen, three kinds of gram negative bacterias of Klebsiella Pneumoniae.These two kinds of medicines are identical to the staphylococcic MIC of epidermis, are 20mg/ml.The Jing Yin granule is 20mg/ml to the MIC of staphylococcus aureus, is lower than the 50mg/ml of SHUANGHUANGLIAN KELI.The Jing Yin granule suppresses the growth of A group streptococcus when 50mg/ml, and SHUANGHUANLIAN when this concentration to A group streptococcus unrestraint effect.Prompting Jing Yin granule slightly is better than SHUANGHUANGLIAN KELI to the antibacterial action of staphylococcus aureus and A group streptococcus.
2.2. serum method
With SHUANGHUANGLIAN KELI and the positive contrast medicine of cefalexin, testing drug is to staphylococcus aureus, colon bacillus, A group streptococcus, the antibacterial action of Klebsiella Pneumoniae.
Clothes Jing Yin granule rabbit anteserum, clothes SHUANGHUANGLIAN KELI rabbit anteserum and normal control rabbit anteserum all do not have antibiotic effect in each concentration to colon bacillus and Klebsiella Pneumoniae.Staphylococcus aureus and A group streptococcus are grown in containing the culture medium of normal rabbit serum in the culture medium control tube that does not more contain serum for few, and clothes Jing Yin granule rabbit anteserum kimonos SHUANGHUANGLIAN KELI rabbit anteserum makes being grown in of these 2 kinds of antibacterials grow still less or not grow than normal serum in the higher culture medium of concentration, and prompting has certain inhibitory action.The cefalexin rabbit anteserum all is utmost point significant inhibitory effect to 4 kinds of antibacterials being tried.
3. immunity test
Heavy dose of group of Jing Yin granule and middle dosage group can significantly improve the phagocytic percentage and the phagocytic index (P＜0.05) of Turnover of Mouse Peritoneal Macrophages.Point out this medicine that the mice non-specific immunity is had certain potentiation.
4. antiinflammatory test
The effect of ear swelling due to the anti-dimethylbenzene of table 4 Jing Yin granule
Group number of animals swelling rate
(a)
Normal control group 10 1.660 ± 0.184
Positive controls 10 1.341 ± 0.239
*
Jing Yin small dose group 10 1.296 ± 0.203
*
And dosage group 10 1.378 ± 0.360 in the silver
*
The heavy dose of group 10 1.466 ± 0.220 of Jing Yin
*
(a) swelling rate=(cause scorching ear weigh-do not cause scorching ear heavy)/do not cause scorching ear is heavy
*P＜0.05
**P＜0.0?1
The large, medium and small dosage group of Jing Yin granule all has the effect of anti-dimethylbenzene induced mice auricle edema, wherein the effect of small dose group is remarkable, compared highly significant difference (P＜0.01) with physiology eye water group, big or middle dosage group compares with the normal saline group that also there were significant differences (P＜0.05).
5. cough-relieving test
The method of coughing is drawn in the Cavia porcellus mechanical stimulus: the codeine group has significant antitussive effect, and effect is fast and lasting.Suppress on the percentile numerical value from cough, each dosage group of Jing Yin has cough-relieving trend, little, the heavy dose of group of Jing Yin 30min after medication wherein, and the heavy dose of group of Jing Yin is at 60min, and its cough suppresses percentage rate and compares with the normal control group that there were significant differences (P＜0.05).
Carry out relevant toxicity test with preparation of the present invention:
1. acute toxicity: the maximum tolerated dose that the Jing Yin preparation is irritated the stomach mice is crude drug 200g/kg.
2. long term toxicity test: give SD rats gavaged Jing Yin preparation (extractum), establish high, medium and low three dosage groups and matched group, be equivalent to crude drug 6g, 25g, 100g/kg respectively, maximum dose level is 60 times of clinical dosage.Matched group gives normal feedstuff.The administration cycle: once a day, continuous one month, observed for two weeks after the drug withdrawal.Observe general situation every day, measure body weight and food-intake weekly.Rat is movable from start to finish normal as a result, any symptom or death do not occur.Administration end and convalescent period, the blood of animal, serum biochemistry, uroscopy all took place significantly to change when stopping, and each organ weights and coefficient are not also seen tangible tendency variation; Histopathologic examination, no significant difference between medication group and matched group is not also seen the specificity pathological change relevant with empirical factor.
Conclusion: prompting Jing Yin preparation is safe in utilization.
By the diagnostic criteria of dialectical standard of traditional Chinese medical science wind and heat in the lung meridian disease and doctor trained in Western medicine upper respiratory tract infection (flu), carry out clinical research with Jing Yin granule and Jing Yin mixture to going into to organize patient, every group 30 example, the result shows as follows:
Jing Yin granule therapy upper respiratory tract infection (wind and heat in the lung meridian card) obvious effective rate 66.67%, total effective rate 96.67%, Jing Yin mixture obvious effective rate 63.33%, total effective rate 96.67% compares with SHUANGHUANGLIAN KELI, all no difference of science of statistics.Studies show that the upper respiratory tract infection determined curative effect of Jing Yin preparation for treating wind and heat in the lung meridian card is reliable, and certain antivirus action is arranged.Safety evaluatio explanation, Jing Yin preparation be to liver, renal function, routine blood test, and routine urinalysis and stool routine have no adverse reaction, and erythra and anaphylaxis do not appear in 60 routine test patients.
Prompting Jing Yin preparation is clinical safe in utilization effective.
The specific embodiment
The preparation of embodiment 1 Jing Yin mixture
Get Herba Schizonepetae 14kg, Flos Lonicerae 15kg, Ilex purpurea Hassk.[I.chinensis Sims 30kg, Herba Houttuyniae 30kg, Folium Isatidis 30kg, Herba Taraxaci 20kg, Radix Saposhnikoviae 14kg, Fructus Arctii 9kg and Radix Glycyrrhizae 6kg, adding water 1680L decocted 20 minutes, be total to secondary, collecting decoction filters, and concentrates, with sucrose 10kg, ethylparaben 0.1kg, sodium benzoate 0.6kg, adjust volume to 200L, packing, sterilization is promptly.
The preparation of embodiment 2 Jing Yin oral liquids
1. get Herba Schizonepetae 21kg, Flos Lonicerae 12kg extracts Aromatic water with steam distillation, other puts.
2. get step 1 medicinal residues and Ilex purpurea Hassk.[I.chinensis Sims 20kg, Herba Houttuyniae 25kg, Folium Isatidis 30kg, Herba Taraxaci 30kg, Radix Saposhnikoviae 17kg, Fructus Arctii 10kg and Radix Glycyrrhizae 6kg, add 65% ethanol extraction secondary, each 40 minutes, merge secondary raffinate, reclaim ethanol, being concentrated into relative density is the clear paste of 1.06-1.08 (90 ℃), adds ethanol and makes and contain alcohol amount to 60%, and cold preservation is more than 48 hours, reclaim ethanol and be concentrated into and do not have the alcohol flavor, thin up is to 120L, and cold preservation filtered more than 48 hours, in filtrate, add Herba Schizonepetae and Flos Lonicerae Aromatic water, stevioside, sorbic acid, Fructus Citri Limoniae essence, add water and adjust volume to 200L, embedding, sterilization, promptly.
The particulate preparation of embodiment 3 Jing Yin
1. get Herba Schizonepetae 420g and add 3000ml water, extract volatile oil with steam distillation, must about 2.5ml Herba Schizonepetae volatile oil, the aqueous solution after distillation device is in addition collected.
2. take by weighing beta-schardinger dextrin-20g, adding distil water 400ml heating for dissolving slowly adds Herba Schizonepetae oil, restir 1.5h while stirring in the time of 40 ℃, leave standstill, cold preservation 24h filters, and uses the washing with alcohol filtering residue, dry,, get Herba Schizonepetae volatile oil Benexate Hydrochloride 14g at 60 ℃ of dry 2h.
3. get step 1 medicinal residues and Flos Lonicerae 700g, Ilex purpurea Hassk.[I.chinensis Sims 1400g, Herba Houttuyniae 1400g, Folium Isatidis 1400g, Herba Taraxaci 1400g, Radix Saposhnikoviae 420g, Fructus Arctii 420g and Radix Glycyrrhizae 280g, decoct with water secondary, each 1 hour, amount of water is 70 liters for the first time, amount of water is 60 liters for the second time, merge the secondary decocting liquid, filter, filtrate and above-mentioned aqueous solution merge, be concentrated into an amount of, add ethanol and make that to contain alcohol amount be 70%, place, get supernatant concentration and become clear paste 1.4kg (relative density 1.22～1.25,90 ℃), add dextrin 2.65kg, microcrystalline Cellulose 0.15kg, Herba Schizonepetae volatile oil Benexate Hydrochloride 14g, mixing is made the 3.5kg granule, dry, packing, every bag 6.5g contains protocatechualdehyde 0.65mg.
The capsular preparation of embodiment 4 Jing Yin
1. get Herba Schizonepetae 520g supercritical CO
2Extraction volatile oil must about 15ml Herba Schizonepetae extract.
2. take by weighing hydroxypropyl 20g, adding distil water 300ml heating for dissolving slowly adds Herba Schizonepetae extract while stirring in the time of 40 ℃, stirs the 1h postlyophilization, gets about the about 20g of Herba Schizonepetae volatile oil hydroxypropyl clathrate.
3. get step 1 medicinal residues and Flos Lonicerae 600g, Ilex purpurea Hassk.[I.chinensis Sims 1400g, Herba Houttuyniae 1400g, Folium Isatidis 1400g, Herba Taraxaci 1400g, Radix Saposhnikoviae 420g, Fructus Arctii 420g and Radix Glycyrrhizae 280g, add 75% ethanol extraction secondary, 60 minutes for the first time, 45 minutes for the second time, each alcohol adding amount is 70L, merge the secondary ethanol extract, filter, reclaim ethanol and be concentrated into relative density 1.08-1.10, spray drying gets the about 1.1kg of dry powder, add 20g Herba Schizonepetae volatile oil hydroxypropyl clathrate, promptly encapsulated behind the mixing.
Embodiment 5
1. get Herba Schizonepetae 1.68kg and extract, get the 10ml Herba Schizonepetae volatile oil, add 200ml ethanol, get the Herba Schizonepetae oil alcoholic solution with steam distillation.
2. get step 1 medicinal residues and Flos Lonicerae 2.8kg, Ilex purpurea Hassk.[I.chinensis Sims 5.6kg, Herba Houttuyniae 5.6kg, Folium Isatidis 5.6kg, Herba Taraxaci 5.6kg, Radix Saposhnikoviae 1.68kg, Fructus Arctii 1.68kg and Radix Glycyrrhizae 1.12kg, decoct with water 2 times, 45 minutes for the first time, 30 minutes for the second time, merge the secondary decocting liquid, filter, be concentrated in right amount, high speed centrifugation is got supernatant concentration and is become clear paste 6kg, add dextrin 12kg, make granule, spray into the Herba Schizonepetae volatile oil alcoholic solution, mixing dries, packing, every bag 6.5g contains protocatechualdehyde 0.8mg.
Claims (10)
1, a kind of Chinese medicine preparation for the treatment of respiratory tract infection and viral influenza is characterized in that said preparation is is the oral formulations that active component is made with Herba Schizonepetae, Flos Lonicerae, Ilex purpurea Hassk.[I.chinensis Sims, Herba Houttuyniae, Folium Isatidis, Herba Taraxaci, Radix Saposhnikoviae, Fructus Arctii and Radix Glycyrrhizae.
2, Chinese medicine preparation according to claim 1 is characterized in that the percentage by weight of wherein said each raw material of active component is formed preferred Herba Schizonepetae 3-11%, Flos Lonicerae 3-11%, Ilex purpurea Hassk.[I.chinensis Sims 11-21%, Herba Houttuyniae 11-21%, Folium Isatidis 11-21%, Herba Taraxaci 11-21%, Radix Saposhnikoviae 3-11%, Fructus Arctii 3-11% and Radix Glycyrrhizae 2-8%.
3, Chinese medicine preparation according to claim 1 is characterized in that wherein said oral formulations comprises granule, capsule, oral liquid or tablet etc.
4, the preparation method of Chinese medicine preparation according to claim 1 is characterized in that this method comprises:
Directly each active raw materials water or alcohol are decocted extraction acquisition concentrated extract, make various preparations according to a conventional method;
Or extract earlier the volatile oil of Herba Schizonepetae or Flos Lonicerae, and will extract then that other medical materials of respectively distinguishing the flavor of merge in residue and the prescription behind the volatile oil, concentrate acquisition extractum after water or the alcohol extraction; The volatile oil that from Herba Schizonepetae, extracts can be directly or with behind the cyclodextrin inclusion technique enclose with extract extractum and pharmaceutic adjuvant and make various preparations according to a conventional method.
5, the preparation method of Chinese medicine preparation according to claim 4 is characterized in that wherein the preparation method of oral liquid comprises:
Get the Herba Schizonepetae and the Flos Lonicerae of recipe quantity and extract volatile oil, the aqueous solution after distillation device is in addition collected;
Herba Schizonepetae behind the extraction volatile oil and Flos Lonicerae medicinal residues and the medicinal component of remaining recipe quantity add extraction solvent and extract secondary, merge extractive liquid,, filter, filtrate concentrates, and adds precipitant, place, get supernatant and filter, concentrate aqueous precipitation, filter, concentrate, aqueous solution, correctives and antiseptic after adding volatile oil and distilling are made oral liquid according to a conventional method.
6, the preparation method of Chinese medicine preparation according to claim 4 is characterized in that wherein the preparation method of solid preparation comprises:
A. extract volatile oil: the Herba Schizonepetae of getting recipe quantity is extracted volatile oil, and other puts; Or with volatile oil cyclodextrin inclusion technique enclose, place, filter, washing, drying makes the cyclodextrin clathrate that contains Herba Schizonepetae volatile oil;
B. get the medicinal component of recipe quantity except that Herba Schizonepetae, add the residue after Herba Schizonepetae is extracted volatile oil, add extraction solvent and extract secondary, merge extractive liquid, filters, and filtrate concentrates, and adds precipitant, and placement is spent the night, and gets supernatant and makes clear paste;
C. get step B and make clear paste and pharmaceutic adjuvant, contain Herba Schizonepetae volatile oil cyclodextrin clathrate mix homogeneously, make granule, capsule or tablet according to a conventional method;
Or get that step B makes clear paste and the pharmaceutic adjuvant mix homogeneously is made granule, or the drying technology makes fine powder, sprays into Herba Schizonepetae volatile oil, makes solid preparation according to a conventional method.
7,, it is characterized in that wherein said extraction solvent is selected from the alcoholic solution of water or 30-90% according to the preparation method of each described Chinese medicine preparation of claim 4 to 6; Precipitant is the 75-95% alcoholic solution.
8,, it is characterized in that wherein said essential oil extraction method comprises steam distillation or super critical extraction according to the preparation method of each described Chinese medicine preparation of claim 4 to 6; The Herba Schizonepetae volatile oil cyclodextrin inclusion technique is meant saturated water solution method, polishing, liquid-liquid method, and wherein used enclose material is a cyclodextrin, comprises beta-schardinger dextrin-or hydroxypropyl.
9, the preparation method of Chinese medicine preparation according to claim 6 is characterized in that wherein said dry technology comprises vacuum drying, spray drying and Freeze Drying Technique.
10, according to the application of the described Chinese medicine preparation of claim 1 in preparation treatment respiratory tract infection and viral influenza medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200310122718XA CN100473398C (en) | 2003-12-19 | 2003-12-19 | Chinese medicine preparation for treating respiratory tract infection and virus flu, preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200310122718XA CN100473398C (en) | 2003-12-19 | 2003-12-19 | Chinese medicine preparation for treating respiratory tract infection and virus flu, preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1552433A true CN1552433A (en) | 2004-12-08 |
| CN100473398C CN100473398C (en) | 2009-04-01 |
Family
ID=34338714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200310122718XA Expired - Lifetime CN100473398C (en) | 2003-12-19 | 2003-12-19 | Chinese medicine preparation for treating respiratory tract infection and virus flu, preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100473398C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457166C (en) * | 2006-01-23 | 2009-02-04 | 李月芬 | Chinese medicinal preparation for treating viral influenza |
| CN102641356A (en) * | 2012-05-21 | 2012-08-22 | 深圳市齐旺投资有限公司 | Traditional Chinese medicine composition for treating respiratory tract viral infectious diseases and preparation method thereof |
| CN104840642A (en) * | 2015-05-16 | 2015-08-19 | 臧海阳 | Traditional Chinese medicine combination for treating wind-heat invading phenotype cold and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1185005C (en) * | 2003-04-26 | 2005-01-19 | 吉林市中心医院 | Medicine for treating inflammation |
-
2003
- 2003-12-19 CN CNB200310122718XA patent/CN100473398C/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457166C (en) * | 2006-01-23 | 2009-02-04 | 李月芬 | Chinese medicinal preparation for treating viral influenza |
| CN102641356A (en) * | 2012-05-21 | 2012-08-22 | 深圳市齐旺投资有限公司 | Traditional Chinese medicine composition for treating respiratory tract viral infectious diseases and preparation method thereof |
| CN102641356B (en) * | 2012-05-21 | 2014-12-10 | 深圳市齐旺投资有限公司 | Traditional Chinese medicine composition for treating respiratory tract viral infectious diseases and preparation method thereof |
| CN104840642A (en) * | 2015-05-16 | 2015-08-19 | 臧海阳 | Traditional Chinese medicine combination for treating wind-heat invading phenotype cold and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100473398C (en) | 2009-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1287830C (en) | Chinese traditional medicine compound preparation for treating gynecopathy and preparation method thereof | |
| CN1293898C (en) | Medicine composition for treating viral hepatitis and its preparation method | |
| CN1168488C (en) | Chinese medicinal preparation for treating pyretic stranguria | |
| CN1298362C (en) | Compound Chinese medicine prepn for treating pulvic infection and its prepn process | |
| CN1552433A (en) | Chinese medicine preparation for treating respiratory tract infection and virus flu, preparing method thereof | |
| CN1899499A (en) | Chinese medicine composition for treating cold and its preparing method and use | |
| CN1899560A (en) | Compound preparation for treating summer wet type cold and its preparing method | |
| CN103316103B (en) | Coccidian-expelling and dysentery-stopping mixture for livestock and preparation method thereof | |
| CN1729992A (en) | External bath lotion for epidemic common cold due to wind-cold | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN102205109B (en) | Chinese medicinal composition for treating rheumatism and application thereof | |
| CN1215595A (en) | External use medicine for treating soft tissue injury and its producing method | |
| CN101829188B (en) | Medicament for treating urinary infection and lithiasis | |
| CN100339126C (en) | Chinese traditional medicine for preventing and treating biliary tract inflammation and its preparation process | |
| CN1397329A (en) | Medicine for treating acne and its preparing process | |
| CN113101331B (en) | Thyme herb tea and preparation method and application thereof | |
| CN101862392B (en) | New pharmaceutical application of cordate houttuynia in thrombus prevention | |
| CN1291738C (en) | Anti-phlogistic anti-viral medicine compositon and technique for preparing the same | |
| CN106377651A (en) | Preparation method for extracting pharmaceutical monomer for preventing and treating hyperuricemia and gout from rhizoma smilacis glabrae | |
| CN1304043C (en) | Longhedan pills and their preparation | |
| CN1923230A (en) | Medicine for treating rheumatism and rheumatoid disease, and its preparation method | |
| CN1189208C (en) | Chinese medicine composition for curing child common cold fever | |
| CN1259938C (en) | Chinese medicine compound preparation for treating cough and its preparing method | |
| CN108420920A (en) | A kind of Chinese medicine composition and preparation method thereof for controlling edema type ephritis | |
| CN100502909C (en) | Chinese-western medicine composition containing cimetidine for treating acne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 201703, Shanghai Qingpu District, Shanghai Qing Ping highway 3500 Patentee after: SPH XING LING SCI. & TECH. PHARMACEUTICAL Co.,Ltd. Address before: 200127 No. 1271 Dongfang Road, Shanghai, Pudong Patentee before: SHANGHAI XING LING SCI. & TECH. PHARMACEUTICAL CO.,LTD. |
|
| CP02 | Change in the address of a patent holder |
Address after: 201707 No. 1991, Huaqing Road, Qingpu District, Shanghai Patentee after: SPH XING LING SCI. & TECH. PHARMACEUTICAL Co.,Ltd. Address before: 201703, Shanghai Qingpu District, Shanghai Qing Ping highway 3500 Patentee before: SPH XING LING SCI. & TECH. PHARMACEUTICAL Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder | ||
| CX01 | Expiry of patent term |
Granted publication date: 20090401 |
|
| CX01 | Expiry of patent term |